Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody

Transl Oncol. 2021 Sep 30;14(12):101232. doi: 10.1016/j.tranon.2021.101232. Online ahead of print.ABSTRACTThe pancaner molecule CD276 (B7-H3) is an attractive target for antibody based therapy. We identified from a large (1011) phage-displayed single-chain variable fragment (scFv) library, a fully human antibody, B11, which bound with high avidity (KD=0.4 nM) to CD276. B11 specifically bound to the V1/V2 domain of CD276 and competed with the antibody 8H9 (Omburtamab). It was used to design an IgG-format bispecific T cell engager B11-BiTE, which was more effective than 8H9-BiTE in 14 different cancer cell lines. B11-BiTE also exhibited strong ADCC/ADCP. Therefore, the fully human B11-BiTE is a promising candidate for treatment of tumors expressing CD276.PMID:34601396 | DOI:10.1016/j.tranon.2021.101232

Source: Translational Oncology - October 3, 2021 Category: Cancer & Oncology Authors: Xianglei Liu Doncho Zhelev Cynthia Adams Chuan Chen John W Mellors Dimiter S Dimitrov Source Type: research